Literature DB >> 17290308

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.

Hongbing Zhang1, Natalia Bajraszewski, Erxi Wu, Hongwei Wang, Annie P Moseman, Sandra L Dabora, James D Griffin, David J Kwiatkowski.   

Abstract

The receptor tyrosine kinase/PI3K/Akt/mammalian target of rapamycin (RTK/PI3K/Akt/mTOR) pathway is frequently altered in tumors. Inactivating mutations of either the TSC1 or the TSC2 tumor-suppressor genes cause tuberous sclerosis complex (TSC), a benign tumor syndrome in which there is both hyperactivation of mTOR and inhibition of RTK/PI3K/Akt signaling, partially due to reduced PDGFR expression. We report here that activation of PI3K or Akt, or deletion of phosphatase and tensin homolog (PTEN) in mouse embryonic fibroblasts (MEFs) also suppresses PDGFR expression. This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1-/- and Tsc2-/- cells. Akt activation in response to EGF in Tsc2-/- cells was also reduced. Furthermore, Akt activation in response to each of EGF, IGF, and PMA was reduced in cells lacking both PDGFRalpha and PDGFRbeta, implying a role for PDGFR in transmission of growth signals downstream of these stimuli. Consistent with the reduction in PI3K/Akt signaling, in a nude mouse model both Tsc1-/- and Tsc2-/- cells had reduced tumorigenic potential in comparison to control cells, which was enhanced by expression of either active Akt or PDGFRbeta. In conclusion, PDGFR is a major target of negative feedback regulation in cells with activated mTOR, which limits the growth potential of TSC tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290308      PMCID: PMC1784000          DOI: 10.1172/JCI28984

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation.

Authors:  Irina Kratchmarova; Blagoy Blagoev; Mandana Haack-Sorensen; Moustapha Kassem; Matthias Mann
Journal:  Science       Date:  2005-06-03       Impact factor: 47.728

Review 2.  The biology of platelet-derived growth factor.

Authors:  R Ross; E W Raines; D F Bowen-Pope
Journal:  Cell       Date:  1986-07-18       Impact factor: 41.582

3.  Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy.

Authors:  A Andrews; E Balciunaite; F L Leong; M Tallquist; P Soriano; M Refojo; A Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-10       Impact factor: 4.799

Review 4.  Oncogenic derivatives of platelet-derived growth factor receptors.

Authors:  A V Jones; N C P Cross
Journal:  Cell Mol Life Sci       Date:  2004-12       Impact factor: 9.261

5.  Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance.

Authors:  M Maxwell; S P Naber; H J Wolfe; T Galanopoulos; E T Hedley-Whyte; P M Black; H N Antoniades
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

6.  Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.

Authors:  Heidi Kenerson; Trevor A Dundon; Raymond S Yeung
Journal:  Pediatr Res       Date:  2004-11-19       Impact factor: 3.756

7.  Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

Authors:  Laifong Lee; Paul Sudentas; Brian Donohue; Kirsten Asrican; Aelaf Worku; Victoria Walker; Yanping Sun; Karl Schmidt; Mitchell S Albert; Nisreen El-Hashemite; Alan S Lader; Hiroaki Onda; Hongbing Zhang; David J Kwiatkowski; Sandra L Dabora
Journal:  Genes Chromosomes Cancer       Date:  2005-03       Impact factor: 5.006

8.  Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.

Authors:  O Jameel Shah; Zhiyong Wang; Tony Hunter
Journal:  Curr Biol       Date:  2004-09-21       Impact factor: 10.834

9.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.

Authors:  Michael N Corradetti; Ken Inoki; Nabeel Bardeesy; Ronald A DePinho; Kun-Liang Guan
Journal:  Genes Dev       Date:  2004-07-01       Impact factor: 11.361

10.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins.

Authors:  Laura S Harrington; Greg M Findlay; Alex Gray; Tatiana Tolkacheva; Simon Wigfield; Heike Rebholz; Jill Barnett; Nick R Leslie; Susan Cheng; Peter R Shepherd; Ivan Gout; C Peter Downes; Richard F Lamb
Journal:  J Cell Biol       Date:  2004-07-12       Impact factor: 10.539

View more
  164 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma.

Authors:  Alan L Ho; Shyamprasad Deraje Vasudeva; Marick Laé; Tsuyoshi Saito; Violetta Barbashina; Cristina R Antonescu; Marc Ladanyi; Gary K Schwartz
Journal:  Cancer Res       Date:  2012-07-10       Impact factor: 12.701

3.  Platelet-derived growth factor-mediated induction of the synaptic plasticity gene Arc/Arg3.1.

Authors:  Fuwang Peng; Honghong Yao; Xuetao Bai; Xuhui Zhu; Benjamin C Reiner; Michael Beazely; Keiko Funa; Huangui Xiong; Shilpa Buch
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

Review 4.  Primary cilia and coordination of receptor tyrosine kinase (RTK) signalling.

Authors:  Søren T Christensen; Christian A Clement; Peter Satir; Lotte B Pedersen
Journal:  J Pathol       Date:  2011-11-21       Impact factor: 7.996

Review 5.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

Review 6.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

7.  Curcumin disrupts the Mammalian target of rapamycin-raptor complex.

Authors:  Christopher S Beevers; Long Chen; Lei Liu; Yan Luo; Nicholas J G Webster; Shile Huang
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

Review 8.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

9.  mTOR promotes pituitary tumor development through activation of PTTG1.

Authors:  R Chen; J Duan; L Li; Q Ma; Q Sun; J Ma; C Li; X Zhou; H Chen; Y Jing; S Zhao; X Wu; H Zhang
Journal:  Oncogene       Date:  2016-08-15       Impact factor: 9.867

10.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Authors:  David Akhavan; Alexandra L Pourzia; Alex A Nourian; Kevin J Williams; David Nathanson; Ivan Babic; Genaro R Villa; Kazuhiro Tanaka; Ali Nael; Huijun Yang; Julie Dang; Harry V Vinters; William H Yong; Mitchell Flagg; Fuyuhiko Tamanoi; Takashi Sasayama; C David James; Harley I Kornblum; Tim F Cloughesy; Webster K Cavenee; Steven J Bensinger; Paul S Mischel
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.